Selected Grants
AEROVATE IMPAHCT FUL AV-101-003 IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
Clinical TrialPrincipal Investigator · Awarded by Aerovate Therapeutics, Inc · 2023 - 2024IMPAHCT Aerovate AV-101-002. IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24- Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH).
Clinical TrialPrincipal Investigator · Awarded by Aerovate Therapeutics, Inc · 2022 - 2024External Relationships
- Sanofi
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.